中國先鋒醫藥(01345.HK)獲授予降壓藥再寧平的大陸獨家特許權
格隆匯 8 月 10日丨中國先鋒醫藥(01345.HK)宣佈,公司全資附屬公司先鋒醫藥(香港)有限公司與Recordati Ireland已訂立一項特許及供應協議。根據該協議,公司獲授予(其中包括)有關Recordati Ireland的再寧平10毫克7Tb及再寧平20毫克7Tb產品(統稱"再寧平產品")於中國大陸的獨家營銷、推廣、分銷及銷售權。受限於該協議的條款及規定,該協議在效至2025年12月31日,且可經雙方同意後重續。
集團一向積極從海外藥品及醫療器材公司物色具有前景的潛在產品以供營銷、推廣及銷售。是次訂立該協議正體現集團持續開發其產品組合的長遠戰略。集團現有醫藥產品及醫療器材的產品組合涵蓋數個醫療專科領域,包括治療高血壓。集團預期將繼續憑藉其現有分銷網絡及營銷渠道推出新產品。預期集團根據該協議的獨家營銷、推廣、分銷及銷售再寧平產品的權利將與集團現有業務產生協同效應,併為集團產生進一步收益創造機遇。
根據公開資料,再寧平(樂卡地平)®為一種抗高血壓的鈣通道阻滯劑,可於超過100個國家購得。樂卡地平具有逐步降低血壓數值的效果,避免出現心律不整的情況,並減低心血管病發及其有關死亡率的風險。樂卡地平的脂溶性及高選取性的特性,為其帶來有效而富耐受性的聲譽。由於其保護器官的特點及代謝中立性,患有糖尿病及腎病等其他疾病的病人較能承受樂卡地平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.